Establishment of a neuroblastoma mouse model by subcutaneous xenograft transplantation and its use to study metastatic neuroblastoma

Gao, Qinglei; Chen, C F; Dong, Qingyu; Hou, Li; Chen, Xian; Zhi, Yunlai; Li, X; Lu, Hongting; Zhang, H Y

doi:10.4238/2015.december.8.20

Cited by 3 publications

(1 citation statement)

References 18 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, hallmarks of the microenvironment such as vascular infiltration, CAFs, and tumor-associated macrophages (TAMs) with an M2 phenotype were observed in orthotopic PDX tumors [116]. Continuous xenograft transplantation has also been used to identify genetic changes that tumors undergo during metastasis [117]. Regarding patient-derived tumor cells propagated in vitro, generating non-adherent cell lines by culturing with basic fibroblast growth factor, epidermal growth factor, and B27 without serum more closely mimics primary cell lines both in vitro and in vivo [118].…”

Section: Xenograft Modelsmentioning

confidence: 99%

Developing preclinical models of neuroblastoma: driving therapeutic testing

Ornell

Coburn

2019

BMC biomed eng

View full text Add to dashboard Cite

Despite advances in cancer therapeutics, particularly in the area of immuno-oncology, successful treatment of neuroblastoma (NB) remains a challenge. NB is the most common cancer in infants under 1 year of age, and accounts for approximately 10% of all pediatric cancers. Currently, children with highrisk NB exhibit a survival rate of 40-50%. The heterogeneous nature of NB makes development of effective therapeutic strategies challenging. Many preclinical models attempt to mimic the tumor phenotype and tumor microenvironment. In vivo mouse models, in the form of genetic, syngeneic, and xenograft mice, are advantageous as they replicated the complex tumor-stroma interactions and represent the gold standard for preclinical therapeutic testing. Traditional in vitro models, while high throughput, exhibit many limitations. The emergence of new tissue engineered models has the potential to bridge the gap between in vitro and in vivo models for therapeutic testing. Therapeutics continue to evolve from traditional cytotoxic chemotherapies to biologically targeted therapies. These therapeutics act on both the tumor cells and other cells within the tumor microenvironment, making development of preclinical models that accurately reflect tumor heterogeneity more important than ever. In this review, we will discuss current in vitro and in vivo preclinical testing models, and their potential applications to therapeutic development.

show abstract

Section: Xenograft Modelsmentioning

confidence: 99%

Developing preclinical models of neuroblastoma: driving therapeutic testing

Ornell

Coburn

2019

BMC biomed eng

View full text Add to dashboard Cite

show abstract

Developing liposomal nanomedicines for treatment of patients with neuroblastoma

Gilabert-Oriol¹,

Chernov²,

Deyell

et al. 2018

Lipid Nanocarriers for Drug Targeting

View full text Add to dashboard Cite

Preclinical Models of Neuroblastoma—Current Status and Perspectives

Krawczyk

Kitlińska

2023

Cancers

View full text Add to dashboard Cite

Preclinical in vitro and in vivo models remain indispensable tools in cancer research. These classic models, including two- and three-dimensional cell culture techniques and animal models, are crucial for basic and translational studies. However, each model has its own limitations and typically does not fully recapitulate the course of the human disease. Therefore, there is an urgent need for the development of novel, advanced systems that can allow for efficient evaluation of the mechanisms underlying cancer development and progression, more accurately reflect the disease pathophysiology and complexity, and effectively inform therapeutic decisions for patients. Preclinical models are especially important for rare cancers, such as neuroblastoma, where the availability of patient-derived specimens that could be used for potential therapy evaluation and screening is limited. Neuroblastoma modeling is further complicated by the disease heterogeneity. In this review, we present the current status of preclinical models for neuroblastoma research, discuss their development and characteristics emphasizing strengths and limitations, and describe the necessity of the development of novel, more advanced and clinically relevant approaches.

show abstract

Establishment of a neuroblastoma mouse model by subcutaneous xenograft transplantation and its use to study metastatic neuroblastoma

Cited by 3 publications

References 18 publications

Developing preclinical models of neuroblastoma: driving therapeutic testing

Developing preclinical models of neuroblastoma: driving therapeutic testing

Developing liposomal nanomedicines for treatment of patients with neuroblastoma

Preclinical Models of Neuroblastoma—Current Status and Perspectives

Contact Info

Product

Resources

About